AzTrials
AzTrials

Alcohol Dependence, in RemissionPhase 2NCT05042180

Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence (CRAVR)

A Phase 2 study testing Virtual Reality Cognitive Behavioral Therapy (CRAVR) and CBT in people with Alcohol Dependence, in Remission and Addiction, Alcohol, run by Psychiatric Centre Rigshospitalet at 1 site in Denmark.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The study is a single-blinded, randomized, controlled, 12 months clinical trial. The objective is to investigate the feasibility, effects and side-effects of virtual reality-assisted cognitive behavioral therapy (VR-CBT) vs. cognitive behavioral therapy (CBT) in patients with a diagnosis of alcohol dependence. Read more about this study

Who is it for?
Ages 18 to 70 years
What is being tested?
Virtual Reality Cognitive Behavioral Therapy (CRAVR) and CBT
Could I receive a placebo?
No, everyone receives an active treatment
How many people
102 participants
Where
1 siteDenmark
Study dates
6 Oct 2021to 1 Mar 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Informed oral and written consent
  • Meets criteria for alcohol dependence syndrome according to International Classification of Diseases (ICD) 10, WHO \& Diagnostic and Statistical Manual of Mental Disorder (DSM-5)
  • Age 18 - 70 years old (both included)
  • Minimum 5 'heavy drinking days' in the last month, which is defined as an alcohol intake above 60/48 grams or 5/4 items per. day for resp. men and women over the past 30 days

Who cannot join

  • Other active substance use defined by DUDIT score> 6 (for men)> 2 (for women) and meet the criteria for other drug dependence according to ICD-10 (excluding nicotine)
  • Does not speak or understand Danish
  • Mental retardation or known severe psychiatric illness or other condition where it is assessed that will interfere with participation eg severely impaired vision or hearing.
  • Medical alcohol treatment (disulfiram, acamprosate, naltrexone or nalmefen) within the latest 4 weeks and during the treatment period

Trial locations and contacts

1 site in 1 country.

Anders Fink-Jensen, MD, DMSc contact

+45 22755843

anders.fink-jensen@regionh.dk

Daniel Thaysen Petersen, MD contact

+4528777938

daniel.thaysen.petersen@regionh.dk

Denmark1 site, 1 recruiting
  • Novavi ambulatorierne

    Copenhagen, Frederiksberg, 2000

    Signe W. Düring, MD, PhD, SDUR@novavi.dk

    Recruiting

Other trials in Denmark

About this study

Official title: Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence: A Randomized Controlled Trial (CRAVR)

The study is a single-blinded, randomized, controlled, 12 months clinical trial. The objective is to investigate the feasibility, effects and side-effects of virtual reality-assisted cognitive behavioral therapy (VR-CBT) vs. cognitive behavioral therapy (CBT) in patients with a diagnosis of alcohol dependence.

Read the detailed description

Recruitment of participants:

102 patients will be recruited from the Novaví outpatient clinics, where they will be informed orally and in writing about the research project and, if they are interested, an information meeting is booked. If patients show symptoms of abstinence, these are treated prior to the information meeting by doctors and nurses in Novaví. If the patient then wishes to participate and meets the inclusion criteria, informed consent is obtained and screening is performed using the questionnaires described later. Included patients will then be randomized to either:

  1. Virtual reality-assisted cognitive behavioral therapy (VR-CBT)
  2. Cognitive behavioral therapy (CBT) without VR (control group)

Screening:

At the screening sessions, patients' medical history is obtained, as well as their alcohol intake over the past 30 days recorded via Timeline Follow-Back (TLFB). Patients are also asked about previous alcohol dependence treatment and general information about psychosocial factors incl. education, work, marital status, and functional level using Global Assessment of functioning (GAF). In addition, alcohol-related problems are assessed using the Alcohol Users Identification Test (AUDIT), abstinence using the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar), intake of other drugs using the Drug User Identification Test (DUDIT), and alcohol craving using the Penn Alcohol Craving Scale (PACS). The Becks questionnaires, Depression Inventory 2 (BDI-II) and Beck's Anxiety Inventory (BAI), are included to assess the degree of anxiety and depression, and in addition, tests of mental function are performed using the Screening for Cognitive Impairment in Psychiatry (SCIP).

Intervention:

Included participants will in collaboration with their therapist schedule a standard course of treatment based on national guidelines from health authorities. After inclusion, participants are randomized to either:

  1. 14 sessions of VR-CBT (Group A)
  2. 14 sessions of CBT without VR (Group B, control group)

The participants in group A are exposed to VR-simulated high-risk situations filmed in a restaurant, a pub, at home, at a party or at the supermarket, to trigger alcohol cravings and other high-risk induced reactions of which the participants are subsequently trained to handle by trained therapists using CBT-based techniques.

The participants in group B receive the same treatment without VR exposure. The will be 4 weeks of weekly-biweekly treatment, followed by 20-21 weeks of treatment every 2-3 weeks, which is in line with the standard treatment in the Novaví outpatient clinics. The intervention deviates from standard treatment, as none of the participants receive pharmaceutical alcohol treatment during the treatment period (6 months) except for abstinence treatment if needed.

Randomization and blinding:

After screening a patient (ensuring that all inclusion criteria and no exclusion criteria are met) the patient is included. Participants are randomly allocated to either VR-CBT og CBT, 51 participants in each group. Randomization takes place in REDCap, which is a secure web application for building and managing surveys and databases. Age, sex and alcohol consumption are stratified at the time of inclusion ('heavy drinking days' and alcohol consumption - evaluated by TLFB). The technical setup of the randomization tool is performed in close collaboration with an expert in statistics, which ensures correct functionality before starting the experiment. After randomization, the therapist ensures that the participant receives the correct treatment and performs the alcohol craving assessment during each VR-CBT session unblinded using visual analog score (VAS). The study staff conducting the remaining data collections and the entire data analysis remain blinded until the database is opened at the end of the study. In situations where it is necessary to break the blind, it is possible to change the user rights in REDCap and gain access to the randomization tools. With the randomization tools, it is possible to detect the treatment (VR-CBT or CBT) based on study ID and all activities performed in REDCap are registered in the program.

Follow-up:

Each participant must attend a follow-up visit 3, 6, and 12 months from inclusion, where data collection will take place using the before mentioned questionnaires. The follow-up visit will be approx. 1 hour.

Statistical analysis:

All statistical analyzes are performed using the intention-to-treat principle, where all patients who have become randomized and has received a minimum of 1 session of VR-CBT (group A) or CBT without VR (group B), is included in the analysis. Missing data are implemented through the multiple imputation method and the analyzes are performed in the program "R" with alpha = 0.05 and 2-sided test. All continuous effect measures are analyzed using ANOVA from baseline to most recent measurement, and categorical data are analyzed using chi2 analysis. All data distributions will be assessed for normality by visual inspection of histogram and by Q-Q plots. If data is not normally distributed, log transformation is performed, and if this is not successful, non-parametric testing is used.

Being tested
Virtual Reality Cognitive Behavioral Therapy (CRAVR), CBT
Keywords
Alcohol, Addiction, Virtual Reality, Exposure Therapy, Cognitive Behavioral Therapy
Medical subject headings
Alcoholism, Behavior, Addictive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Virtual Reality Cognitive Behavioral Therapy (CRAVR)Behavioural

    Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.

  • CBTBehavioural

    The active comparator receives 14 conventional cognitive behavioral therapy sessions with

Study groups in NCT05042180
Study groupRoleWhat they receive
Virtual Reality Cognitive Behavioral Therapy (VRCBT)ExperimentalThe VR exposure is performed to induce alcohol craving and high-risk induced reactions during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
Receives: Behavioral: Virtual Reality Cognitive Behavioral Therapy (CRAVR)
Cognitive Behavioral Therapy (CBT)Active comparatorCBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
Receives: Behavioral: CBT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Reduction in total alcohol consumption

    Percent change in alcohol consumption, defined as "x" grams of alcohol for past 30 days. This will be registered using the Timeline-Follow-Back (TLFB) method.

    Measured: Baseline, 6 months, 9 months, 12 months

Secondary outcomes (12)
  1. Change in heavy drinking days

    Based on the past 30 days of alcohol consumption using time line follow-back (TLFB), heavy drinking days are evaluated. 1 heavy drinking day consists of alcohol consumption exceeding 60/48 grams for men and women respectively.

    Measured: Baseline, 6 months, 9 months, 12 months

  2. Change in Alcohol Users Identification Test (AUDIT) score

    Screening for excessive drinking. Higher score = worse outcome

    Measured: Baseline, 6 months, 9 months, 12 months

  3. Change in Drug User Identification Test (DUDIT) score

    Identification of individuals with drug-related problems. Higher score = worse outcome

    Measured: Baseline, 6 months, 9 months, 12 months

  4. Change in Penn Alcohol Craving Scale (PACS) score

    Assessing alcohol craving. Higher score = worse outcome

    Measured: Baseline, 6 months, 9 months, 12 months

  5. Screening for Cognitive Impairment in Psychiatry (SCIP) score

    The 20 minute test is a scale developed for screening cognitive deficits. Higher score = better outcome

    Measured: Baseline, 6 months, 9 months, 12 months

  6. Change in Global Assessment of functioning (GAF) score

    GAF measures to what degree a person's symptoms affect their daily functioning on a scale of 0 to 100. Higher score = better outcome

    Measured: Baseline, 6 months, 9 months, 12 months

  7. Becks Anxiety Inventory (BAI) score

    Measures the severity of anxiety. Higher score = worse outcome

    Measured: Baseline, 6 months, 9 months, 12 months

  8. Becks Depression Inventory 2 (BDI-II) score

    Measures the severity of depression. Higher score = worse outcome

    Measured: Baseline, 6 months, 9 months, 12 months

  9. Simulator Sickness Questionnaire (SSQ)

    Measures whether participants experience symptoms of simulator sickness while in Virtual Reality. Higher score = worse outcome

    Measured: Each of the 14 treatment sessions over 6 months

  10. VR-induced craving on a visual analog scale (VAS)

    For each of the 6 VR-scenes, craving is evaluated before, during and after exposure as well as at the end of the therapy session

    Measured: Each of the 14 treatment sessions over 6 months

  11. Alcohol withdrawal symptoms

    Alcohol withdrawal symptoms are evaluated at inclusion. Higher score = worse outcome

    Measured: Evaluated at inclusion

  12. Qualitative assessment

    15 patients and 5 therapists will be asked about advantages and disadvantages of using virtual reality

    Measured: After completion of a full treatment period of 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Sep 2021
  2. Study start6 Oct 2021
  3. Primary completion1 Mar 2024 (estimated)
  4. Study completion1 Mar 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
single-blinded, randomized, controlled
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
102 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05042180
Sponsor's protocol ID
CRAVR
Status last verified
Nov 2021
First submitted
27 Jul 2021
Last updated
10 Nov 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Thaysen-Petersen D, Hammerum SK, Vissing AC, Oestrich IH, Nordentoft M, During SW, Fink-Jensen A. Virtual reality-assisted cognitive behavioral therapy for patients with alcohol use disorder: a randomized feasibility study. Front Psychiatry. 2024 Feb 14;15:1337898. doi: 10.3389/fpsyt.2024.1337898. eCollection 2024.

    PubMed 38419905
  • Thaysen-Petersen D, Hammerum SK, Vissing AC, Arnfred BT, Nordahl R, Adjorlu A, Nordentoft M, Oestrich IH, During SW, Fink-Jensen A. Virtual reality-assisted cognitive behavioural therapy for outpatients with alcohol use disorder (CRAVR): a protocol for a randomised controlled trial. BMJ Open. 2023 Mar 29;13(3):e068658. doi: 10.1136/bmjopen-2022-068658.

    PubMed 36990475

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Virtual Reality Cognitive Behavioral Therapy (CRAVR) and CBT in people with Alcohol Dependence, in Remission and Addiction, Alcohol, run by Psychiatric Centre Rigshospitalet at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Anders Fink-Jensen, MD, DMSc (+45 22755843, anders.fink-jensen@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Reduction in total alcohol consumption (time frame: Baseline, 6 months, 9 months, 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05042180, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in